US FDA approves Axsome Therapeutics' migraine drug
The U.S. Food and Drug Administration has approved Axsome Therapeutics' migraine treatment, the company said on Thursday. The oral drug, branded Symbravo, was approved for the acute treatment of the condition characterized by recurrent attacks of moderate to severe throbbing and pulsating pain on one side of the head.
FDA approves new type of non-opioid pain medication
FDA approves new type of non-opioid pain medication, 1st of its kind in more than 20 years
The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain.
FDA approves new, non-opioid painkiller Journavx
Vertex Pharmaceuticals Shares Gain After FDA Approves Non-Opioid Pain Drug
Shares of Vertex Pharmaceuticals rose after Journavx, the company’s oral non-opioid pain medication, received Food and Drug Administration approval.
AFP12m
Vertex Announces FDA Approval of JOURNAVX™ (suzetrigine), a First-in-Class Treatment for Adults With Moderate-to-Severe Acute Pain
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain.
The FDA says it has approved a new non-addictive pain medication
(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name Journavx. It is now FDA-approved to treat moderate to severe acute pain, which is usually caused by injury, trauma or surgery.
FDA approves first new type of pain medication in 25 years
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.
What Is Journavx? First Pain Medication Approved by FDA in Over Two Decades
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
MLive6h
This chocolate recall has been upgraded to FDA’s highest risk level
STATEN ISLAND, N.Y. — A December 2024 chocolate recall has been upgraded to highest risk level by the U.S. Food and Drug Administration (FDA), which says consuming the product could “cause serious adverse health consequences or death.”
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
Santa Rosa Press Democrat3m
FDA approves painkiller designed to eliminate the risks of addiction associated with opioids
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.
WCJB1h
FDA approves new non-addictive pain medication
(CNN) – The U.S. Food and Drug Administration approved the first new type of pain medication in more than two decades, and it’s not an opioid. The drug is suzetrigine under the brand name Journavx. It is now FDA-approved to treat moderate to severe acute pain, which is usually caused by injury, trauma or surgery.
Hosted on MSN2h
FDA OKs painkiller designed to cut opioids-linked addiction risk
Federal officials on Thursday approved a new type of pain pill designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin. The US Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often follows surgery or injuries.